Finerenone: First Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

1. Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials.Frontiers in pharmacology · 2023
   Pooled it
2. Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers.Naunyn-Schmiedeberg's archives of pharmacology · 2025
   Trial
3. Defining the potential role of the mineralocorticoid receptor in musculoskeletal health and bone crosstalk with other tissues.The Journal of endocrinology · 2026
   Review
4. Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
   Review
5. Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration.Drugs and drug candidates · 2026
   Article
6. An integrative framework for drug target discovery bridging clinical trial and genetic data insights.Journal of translational medicine · 2026
   Article
7. Contemporary management of advanced chronic kidney disease: An evidence-based review.European journal of internal medicine · 2026
   Review
8. EphrinB2 Ameliorates Renal Fibrosis by Inhibiting the TGF-β/Smad3 Signaling Pathway and the Inflammation ResponseEndocrine, metabolic & immune disorders drug targets · 2026
   Article
9. Aldosterone in Chronic Kidney Disease.Biomedicines · 2025
   Review
10. Stability indicating RP-HPLC method for estimation of finerenone and its related substances in new dosage form.Scientific reports · 2025
    Article
11. New insights in the treatment of DKD: recent advances and future prospects.BMC nephrology · 2025
    Review
12. Exploring the potential of finerenone in non-diabetic chronic kidney disease: a promising frontier.International urology and nephrology · 2025
    Article
13. Finerenone Ameliorates High Glucose-Induced Podocytes Epithelial-Mesenchymal Transition Through the Regulation of Krüppel-Like Factor 5 in Diabetic Nephropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
14. Efficacy and safety of dapagliflozin in children with kidney disease: real-world data.Pediatric nephrology (Berlin, Germany) · 2024
    Article
15. Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study.International urology and nephrology · 2024
    Article
16. Placenta-derived mesenchymal stem cells protect against diabetic kidney disease by upregulating autophagy-mediated SIRT1/FOXO1 pathway.Renal failure · 2024
    Article
17. Curcumin targets CXCL16-mediated podocyte injury and lipid accumulation in diabetic kidney disease treatment.Archives of pharmacal research · 2024
    Article
18. Finerenone: Who should prescribe it for CKD? The physician associate's perspective.Journal of nephrology · 2024
    Review
19. Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models.International journal of molecular sciences · 2024
    Review
20. Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment.Reviews in cardiovascular medicine · 2024
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as